Fibrostenotic Crohn's Disease
Immunology
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Agomab TherapeuticsBelgium - Antwerpen
2 programs1
1
AGMB-129Phase 21 trial
AGMB-129Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
Agomab TherapeuticsAGMB-129
Agomab TherapeuticsAGMB-129
Clinical Trials (2)
STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease
Start: Aug 2023Est. completion: Sep 2026
Phase 2Active Not Recruiting
A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants
Start: Aug 2025Est. completion: Sep 2025
Phase 1Completed
Related Jobs in Immunology
Regulatory Affairs Manager(Immunology), Korea
AbbVie
Seoul, Seoul
15h ago
Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)
AbbVie
Remote
15h ago
Field Reimbursement Manager - Rheumatology - Seattle, WA (North)
Johnson & Johnson
Seattle, Washington, United States of America
Yesterday
$100K - $175K/yr
Senior Medical Science Liaison, Dermatology - Indianapolis
Johnson & Johnson
Indianapolis, Indiana, United States
Yesterday
$137K - $236K/yr
Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine
Johnson & Johnson
Detroit, Michigan, United States
Yesterday
Supply Chain and Procurement Controller
Ferring Pharmaceuticals
Hvidovre, Denmark
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space